Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant

The Efficacy, Safety, and Tolerability of Switching to a Bictegravir (BIC)/Emtricitabine(FTC)/Tenofovir Alafenamide (TAF) Regimen in Virally Suppressed Human Immunodeficiency Viruses (HIV)-Positive Patients Post-Renal Transplant

This is an open-label study, where participants will be switched from their current HIV medication to the study drug, BIC/F/TAF. Open-label means both the investigator and the participant will know what drug will be given. Participants will be followed for 48 weeks in order to monitor the efficacy, safety and tolerability of BIC/F/TAF. The investigator hypothesizes that BIC/F/TAF will be an important addition to the management of HIV-positive post renal transplant patients, especially since it is a one pill daily dosing regimen, thereby decreasing the pill burden in this population.

Inclusion Criteria:

• At least 18 years old on day of signing informed consent
• Positive for human immunodeficiency virus (HIV)
• Received a previous renal transplant
• Must have controlled HIV infection for at least 3 months prior to enrollment

Exclusion Criteria:

• Received a kidney from a donor who was HIV positive (unless a false positive)
• Currently taking BIC/F/TAF for treatment of HIV
• Has allergies to any of the HIV medications in BIC/F/TAF (bictegravir, emtricitabine, or tenofovir alafenamide)
• Currently taking dofetilide or rifampin
• Is pregnant or breastfeeding